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Introduction
• An in silico clinical trial is an individualised computer simulation used in the development of a medicinal product or intervention.
• Expected benefits : provide a mechanistic understanding, optimise the strategies of delivery and improve de clinical trials designs.
• Therapeutic relief is crucial for HIV infected patients under highly active antiretrovirals (ARVs) therapies (HAARTs). Multiple ongoing studies
test mono/bi-therapies or short cycle therapies for HAARTs. In this work, we aim at validating these strategies in silico.
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Estimation Method: R library lme4 [3]
Mechanistic NLME-ODE
Mathematical Model: Ordinary differential
equation (ODE) modeliling CD4 quiescent (Q),
target (T ), infected (T ∗) and viruses (V ).

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Statistical Model: Transition rates modelled
with non linear mixed effect models (NLME).
λi = λ0 + u
λ
i u
λ ∼ N (0, σ2λ)
αi = α0 + u
α
i u
α ∼ N (0, σ2α)






Observation Model: Viral load and CD4.
V Lij = log10(Vi(j)) + εij1




εij1 ∼ N (0, σ21) and εij2 ∼ N (0, σ22)
Estimation Method: NIMROD, penalised
likelihood maximisation for NLME-ODE [4,5]
The Aquitaine ANRS CO3 Cohort [6]
Treatment-naive patients included after 1/1/2000 with at least two follow-up and baseline viral load
> 10, 000 copies/mm3 under investigated ARVs. Total N=248 out of 2550 patients in the cohort.
ARVs Effects
Reasonable concordance between in-
vitro/in-vivo indicators of efficacy.
Two-step One-step NLME
βARVJ LIM LIM ODE
AZT -1.3 [-4.0; 1.6] -1.3 [-2.5; -0.2] -0.33 [-0.36; -0.30]
3TC -3.8 [-7.4; -0.1] -2.8 [-5.0; -0.7] -0.36 [-0.40; -0.32]
FTC -3.7 [-7.4; 0.1] -3.2 [-5.3; -1.0] -0.40 [-0.45; -0.34]
ABC -1.5 [-3.9; 1.1] -1.6 [-2.7; -0.4] -0.29 [-0.32; -0.26]
TEN -1.1 [-3.6; 1.5] -1.5 [-2.7; -0.4] -0.30 [-0.35; -0.24]
EFV -3.8 [-5.9; -1.4] -2.4 [-3.6; -1.2] -0.34 [-0.36; -0.32]
LPV/r -3.5 [-5.6; -1.2] -1.9 [-3.1; -0.7] -0.28 [-0.33; -0.23]
ATA -3.0 [-5.8; -0.1] -2.3 [-3.4; -1.1] -0.35 [-0.36; -0.34]
DRV/r -3.4 [-6.0; -0.5] -2.5 [-3.6; -1.3] -0.34 [-0.36; -0.32]
Reg. -2.1 (p=0.003) -5.3(p<0.001) -13.6 (p=0.005)
Model fitted β× IIP, p-values are for R2 adequation
p-value 0.097 0.097 0.463
Spearman Corr. Instantaneous Inhibitory Potential (IIP) [7]
In silico ARVs relief
Reduction of the number of ARV: The
OLE trial [8], the SALT study [9] and the
MADRID cohort [10] show that regarding viral
control at 48 weeks, DRV/r+3TC (98%) lead to
more successes than LPV/r+3TC (91%), which
is more powerful than ATV+3TC (84%). We
investigate in silico the probability of vi-
ral control at 48 weeks.
In silico Short-cycle therapies
Predictive ability of NLME-ODE [1] are used to
predict the probability to have viral control at




This is consistent with on-going studies. Strate-
gies such as in 4D ANRS 162 [11] shows 96% fo
viral control at 48 weeks with PI or NNRTI +
2NRTI and BREATHER trial [12] shows 94% of
viral control at 48 weeks with EFV + 2NRTI.
Conclusion
• Proof-of-concept, need to add virus mutations & pharmacological modeling
• Optimal design for patient/regimen-specific strategies using Bayesian control [5]
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